Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies
Launched by NATIONAL CANCER INSTITUTE (NCI) · Dec 1, 2018
Trial Information
Current as of July 24, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Background:
Increased understanding of the genomic variations of cancer through laboratory evaluations can result in breakthroughs in treatment and improved patient outcomes.
Exceptional responders on clinical trials may have mutational characteristics that are unique and unknown, necessitating identification.
Current drug development strategies employ precision oncology. This approach identifies molecular targets, with therapies being either chosen or developed to interact with the specific target.
The collection and banking of a variety of tissue samples for future translational studi...
Gender
ALL
Eligibility criteria
- * INCLUSION CRITERIA:
- • Adult subject (age 18 and older) co-enrolled on a trial, or otherwise undergoing consultation, screening, or follow up on existing protocols conducted at the NIH Clinical Center, who are evaluated in the Women s Malignancies Branch Clinic.
- * Participant or biological relative of a participant, as follows:
- • Participant with a histologically confirmed breast cancer or other gynecologic malignancy; histopathology of the biopsy tissue must be
- • confirmed by the NCI Laboratory of Pathology, prior to banking of the tissue on this protocol.
- • Biological relative (1st 3rd degree) of a participant who meets the eligibility of histologically confirmed malignancy per above
- • criterion.
- • Subject willingness and ability to provide informed consent.
- • Subject willingness to provide tissue samples for banking.
- EXCLUSION CRITERIA:
- • - Pregnant individuals are not eligible to take part; pregnancy will be assessed using clinical criteria (medical history and physical exam).
About National Cancer Institute (Nci)
The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
Patients applied
Trial Officials
Jung-Min Lee, M.D.
Principal Investigator
National Cancer Institute (NCI)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials